Buprenorphine sublingual spray - INSYS Therapeutics

Drug Profile

Buprenorphine sublingual spray - INSYS Therapeutics

Latest Information Update: 06 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSYS Pharma
  • Developer INSYS Therapeutics, Inc
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postoperative pain

Most Recent Events

  • 22 May 2018 The US FDA advisory committee does not recommend the use of buprenorphine sublingual spray for Post-operative pain
  • 08 Dec 2017 Planned Prescription Drug User Fee Act (PDUFA) date for Postoperative pain in USA (Sublingual) is 2018-07-28
  • 06 Dec 2017 INSYS Therapeutics completes a phase II trial in Postoperative pain in USA (Sublingual, Spray) (NCT03254459)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top